MedPath

Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency

Phase 4
Completed
Conditions
Weight Gain Trajectory
Metabolic Syndrome
Interventions
Dietary Supplement: Prebiotin
Registration Number
NCT04498455
Lead Sponsor
Baylor University
Brief Summary

A randomized placebo controlled trial to determine if increased dietary fiber will prevent weight gain, inhibit adiposity and reduce perceived stress levels in residents at the Waco Family Health Center as the result of changes in distal gut microbiota composition and function.

Detailed Description

This study will utilize a single blind, placebo controlled, parallel design to assess the effect of dietary fiber \[Prebiotin\] on the gut microbiome, perceived stress, anthropometric variables, and clinical biomarkers of metabolism. All participants in this study will be resident physicians at the Family Health Center in Waco, TX. This population was selected based on pilot data indicating they are at a greater risk for weight gain and have higher levels of stress than the average population. The goal is to recruit 40 participants for a 12 week intervention trial.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
11
Inclusion Criteria
  • Currently a resident in training at the Family Health Center in their first year.
Exclusion Criteria
  • Pregnancy
  • Currently on prescribed metformin or NSAIDS
  • A diagnosed gastro-intestinal disease (i.e. irritable bowel syndrome or Crohn's disease)
  • Known allergy to the supplement, placebo, or provided meal replacements
  • Antibiotic use within the last 3 months.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPrebiotinDietary Supplement: Placebo
PrebiotinPrebiotinDietary Supplement: Prebiotin (oligofructose enriched inulin)
Primary Outcome Measures
NameTimeMethod
Change in body weight12 weeks

The investigators will use the following procedure to assess the effect of Prebiotin (OEI) on changes in body weight: there will be two test days: a) baseline (Day 0), prior to randomization to OEI or placebo; and b) week 12, following the 11 week course of OEI/placebo treatment. The investigators will use OEI for the inulin challenge. Change in body weight will be quantified by bio electrical impedance.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Baylor University

🇺🇸

Waco, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath